Overexpression of GPR35 confers drug resistance in NSCLC cells by β-arrestin/Akt signaling
Wei Wang,1 Tianci Han,1 Wei Tong,1 Jian Zhao,1 Xueshan Qiu2 1Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, China; 2Department of Pathology, The First Hospital of China Medical University, Shenyang 110001, China...
Main Authors: | Wang W, Han T, Tong W, Zhao J, Qiu X |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/overexpression-of-gpr35-confers-drug-resistance-in-nsclc-cells-by-beta-peer-reviewed-article-OTT |
Similar Items
-
The Therapeutic Potential of Orphan GPCRs, GPR35 and GPR55
by: Patricia Hodapp Reggio, et al.
Published: (2015-04-01) -
The Role of β-Arrestin1 in Esophageal Squamous Cell Carcinoma
by: Tan Z, et al.
Published: (2020-03-01) -
The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists
by: Huayun Deng, et al.
Published: (2013-04-01) -
Characterization of Beta-arrestin-Modulated Lipid Kinase Activities for Diacylglycerol and Phosphatidylinositol 4-Phosphate
by: Nelson, Christopher David
Published: (2007) -
The Clinical Significance of β-arrestin 2 Expression in the Serum of
Non-small Cell Lung Cancer Patients
by: Zhengqing WU, et al.
Published: (2011-06-01)